MS Research Studies underway at: Neurological Associates Research
Posted Jan 14 2009 8:26pm
Research Ctr information found below the listing of:
CURRENT ENROLLMENT STUDIES:
Relapsing-Remitting MS - A 24 month study comparing the efficacy and safety of 2 different doses of oralFingolimod versus placebo with an optional extension phase. For more information visit: www.msclinicaltrials.com.
Relapsing- Remitting MS - A 4 year study to compare 2 annual cycles of intravenous low and high dose alemtuzumab(Campath) to three times weekly subcutaneous Rebif in patients who have relapsed on therapy. For more information visit: : www.clinicaltrials.gov/ct2/show/NCT00548405
Relapsing-Remitting MS - A 2 year study comparing safety and efficacy of 2 different doses of oral Fumarate versus placebo with Copaxone as an active comparator. For more information visit: www.clinicaltrials.gov/ct/show/NCT00451451.
Relapsing Remitting MS - an 85 day study to assess safety and efficacy of 2 oral doses of Dextromethorphan/Quinidine in the treatment of Pseudobulbar Affect (inappropriate laughter/crying) with an optional extension phase. For more information visit: www.pbatrial.com.
Relapse-Remitting MS- A 2 year study comparing safety and efficacy of 2 cycles of Alemtuzumab (Campath) intravenous Versus 3 times weekly subcutaneous Interferon Beta-1a (Rebif).
Learn More of the above studies by contacting the office of:Neurological Associates Research (Dr. Brian Steingo) >>>>>Click hereto review contact information
Research Ctr information found below the listing of:
CURRENT ENROLLMENT STUDIES:
Relapsing-Remitting MS - A 24 month study comparing the efficacy and safety of 2 different doses of oralFingolimod versus placebo with an optional extension phase. For more information visit: www.msclinicaltrials.com.
Relapsing- Remitting MS - A 4 year study to compare 2 annual cycles of intravenous low and high dose alemtuzumab(Campath) to three times weekly subcutaneous Rebif in patients who have relapsed on therapy. For more information visit: : www.clinicaltrials.gov/ct2/show/NCT00548405
Relapsing-Remitting MS - A 2 year study comparing safety and efficacy of 2 different doses of oral Fumarate versus placebo with Copaxone as an active comparator. For more information visit: www.clinicaltrials.gov/ct/show/NCT00451451.
Relapsing Remitting MS - an 85 day study to assess safety and efficacy of 2 oral doses of Dextromethorphan/Quinidine in the treatment of Pseudobulbar Affect (inappropriate laughter/crying) with an optional extension phase. For more information visit: www.pbatrial.com.
Relapse-Remitting MS- A 2 year study comparing safety and efficacy of 2 cycles of Alemtuzumab (Campath) intravenous Versus 3 times weekly subcutaneous Interferon Beta-1a (Rebif).
Learn More of the above studies by contacting the office of:Neurological Associates Research (Dr. Brian Steingo)
>>>>>Click hereto review contact information
============================================